Contact Us

Case Review Form
*    Denotes required field.

Describe accident or indicate name of drug or device

   * First Name 

   * Last Name 

   * Email 


   * Please describe your case:

What injury have you suffered?

For verification purposes, please answer the below question:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Xarelto Lawsuits Now Over 5000 and Continuing to Grow

Jul 6, 2016

Barely two months ago, the multidistrict litigation Xarelto lawsuits numbered about 4,500. Today, there are over 5,381 cases pending in U.S. District Court for the Eastern District of Louisiana. For some time, experts have maintained that the way that Xarelto, along with Pradaxa, were brought to market, but requiring less monitoring and having no available antidote, could result in heavy litigation.

Coumadin (warfarin) the tried-and-true anticoagulant, has remained effective as a viable blood thinner for patients with atrial fibrillation or for those at risk for stroke. Stringent blood monitoring and a somewhat rigid diet is required, but an infusion of vitamin K provides an effective antidote in case of sudden bleeds, reports

Although there has always been a risk for uncontrolled bleeding with Coumadin, an emphasis on blood and diet monitoring has been effective in providing a reasonably safe status with warfarin. Like warfarin, there is also a bleed out risk for rivaroxaban (Xarelto).

One plaintiff is suing the Xarelto manufactu on behalf of her husband who suffered a Xarelto bleed out in his brain. He had been taking Xarelto for six months for atrial fibrillation when he died. Another plaintiff is suing on behalf of her father. He had been prescribed Xarelto for only a month due to stroke risk, when he suffered a serious Xarelto bleeding issue in his brain and died, reports

Plaintiffs are alleging that not only was the Xarelto manufacturer negligent in bringing Xarelto to market without an available antidote, but that patients were not adequately advised or warned regarding the lack of a reversing agent, so long a part of the established warfarin equation.

Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo